Clinical Trial: Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07177196) titled 'Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy' on Sept. 02.

Brief Summary: This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Retinal Dystrophy due to PRPH2 mutation

Study Start Date: Aug. 28

Study Type: INTERVENTIONAL

Condition: Retinal Dystrophy

Intervention: DRUG: nL-PRPH2-001

Personalized antisense oligonucleotide

Recruitment Status: ACTIVE_NOT_RECRUITING

Sponsor: n-Lorem Foundation

Disclaimer: Curated by HT Syndication....